8-K: Jaguar Health Designates Series O Preferred Stock for Dividend

Jaguar Health, Inc. filed a Certificate of Designation for its Series O Convertible Preferred Stock, detailing the terms for a special one-time dividend.

Summary

• Jaguar Health, Inc. filed a Certificate of Designation for 1,557,000 shares of Series O Convertible Preferred Stock with the Secretary of State of Delaware on March 2, 2026.
• This filing is in connection with a previously announced special one-time dividend of one-tenth of one share of Series O Preferred Stock for each share of voting common stock and certain eligible warrants.
• The record date for the dividend was March 2, 2026, with payment expected as of the close of business on March 4, 2026.
• Series O Preferred Stock has a par value of $0.0001 per share and a Stated Value of $8.01 for conversion purposes.
• Holders are not entitled to receive dividends on Series O Preferred Stock and have limited voting rights (one vote per one-tenth of one share when entitled to vote).
• The company may optionally convert all Series O Preferred Stock to common stock before December 31, 2026, or it will automatically convert on December 31, 2026.
• Conversion is subject to a 19.99% beneficial ownership limitation, with pre-funded warrants issued for any excess shares.
• There is no established trading market for Series O Preferred Stock, and the company does not expect one to develop or intend to list it on any securities exchange.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event in terms of immediate sentiment. It's a procedural filing detailing a previously announced dividend, with both potential benefits (rewarding shareholders) and drawbacks (illiquid preferred shares, conversion limitations).

Positives

• The issuance of Series O Preferred Stock facilitates a special one-time dividend to common stockholders and eligible warrant holders, rewarding existing investors.
• Series O Preferred Stock holders have a preferential payment of $0.0001 per share in a liquidation event before common stockholders, subject to the rights of the company's depositors and other creditors.

Negatives

• Series O Preferred Stock cannot be transferred, assigned, or pledged by any holder at any time without the company's prior written consent, limiting liquidity.
• Holders of Series O Preferred Stock are not entitled to receive any dividends on these shares.
• Series O Preferred Stock generally has no voting rights, except as specifically provided or required by law, and then only one vote per one-tenth of a share.
• There is no established trading market for Series O Preferred Stock, and the company does not expect one to develop or intend to apply for listing on any securities exchange or nationally recognized trading system.
• Conversion to common stock is subject to a 19.99% beneficial ownership limitation, potentially leading to the issuance of pre-funded warrants instead of common shares if the limit is exceeded.

Risks

• The lack of an established trading market for Series O Preferred Stock means holders may not be able to readily sell or transfer their shares, impacting liquidity.
• The conversion limitations (Maximum Percentage of 19.99%) could prevent holders from receiving all their conversion shares as common stock, instead receiving less liquid pre-funded warrants.
• The value of the conversion shares is dependent on the future common stock price, which is subject to market fluctuations and inherent risks of equity investments.

Future Outlook

The Series O Preferred Stock is subject to optional conversion by the company at any time prior to December 31, 2026, or will automatically convert to common stock on December 31, 2026. The conversion price will be based on the common stock's market price around the conversion date.

Management Comments

• Lisa A. Conte and Carol R. Lizak certified their roles as Chief Executive Officer/President and Chief Financial Officer, respectively, of Jaguar Health, Inc. in the Certificate of Designation.

Industry Context

StockSavvy.ai notes that special dividends, particularly those involving preferred stock, can be a strategy for companies to reward existing shareholders or manage their capital structure without immediate cash outflow. The use of convertible preferred stock with specific conversion terms and limitations is common in situations where a company aims to control potential dilution or maintain certain ownership thresholds.

Comparison to Industry Standards

• This type of preferred stock dividend with conversion limitations and no trading market is not a standard cash dividend. It is more akin to a complex financial instrument designed for specific corporate finance objectives.
• Unlike a typical cash dividend from a mature company like Apple (AAPL) or Microsoft (MSFT) which are regular and cash-based, this is a one-time, non-cash dividend with specific conversion mechanics.
• It shares some characteristics with 'poison pill' preferred stock issuances designed to deter hostile takeovers, though the stated purpose here is a dividend.
• The lack of a trading market for the preferred shares is unusual for a dividend instrument intended for broad distribution, contrasting with publicly traded preferred shares issued by financial institutions like JPMorgan Chase (JPM) or Bank of America (BAC) which offer liquidity.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Receive a special one-time dividend in the form of Series O Preferred Stock, which will eventually convert to common stock, potentially increasing their ownership percentage (subject to limitations).
• Holders of Eligible Warrants: Also receive the special dividend, aligning their interests with common stockholders.
• Future Investors: May need to understand the implications of the Series O Preferred Stock and its conversion mechanics on the common stock float and potential dilution.

Next Steps

• Payment of the Preferred Stock Dividend is expected as of the close of business on March 4, 2026.
• The Series O Preferred Stock will either be optionally converted by the Company or automatically convert to Common Stock on December 31, 2026.

Key Dates

Recommendation

This filing is primarily a procedural update detailing the terms of a previously announced special dividend in preferred stock. It does not contain new financial performance data or strategic shifts that would warrant a strong buy or sell recommendation. The dividend itself is a positive for existing shareholders, but the illiquidity and conversion complexities of the Series O Preferred Stock suggest a neutral 'hold' stance until the full impact of the conversion on the common stock is clearer.

Keywords

Jaguar Health, JAGX, Series O Preferred Stock, Convertible Preferred Stock, Special Dividend, SEC Filing, 8-K, Corporate Governance, Stock Dividend, Preferred Stock Terms